White Kidney Bean Extract Over 45 Days: 2.1 kg Weight Loss, 6.4 cm Waist Reduction in Controlled Trial
The idea of taking a capsule before a meal to blunt carbohydrate absorption has been around for decades. What the clinical numbers actually look like is a different question.
A randomized, double-blind, placebo-controlled trial published in Heliyon examined Phaseolean, a standardized water extract of white kidney bean (Phaseolus vulgaris), over 45 days in 66 overweight and obese adults. The study tested whether a proprietary alpha-amylase inhibitor could meaningfully reduce body weight and fat mass under controlled dietary conditions.
Study Design
62 participants completed the trial (47 women, 15 men; mean age 35.8 years; BMI 25–35). They were randomly assigned to one of three groups.
- Group A: 1,500 mg Phaseolean per day (500 mg per meal, three times daily)
- Group B: 3,000 mg Phaseolean per day (1,000 mg per meal, three times daily)
- Group C: Matched placebo
All participants followed a standardized diet of approximately 2,000 kcal per day (61% of calories from carbohydrates) and performed 45 minutes of brisk walking daily. This standardization allowed researchers to isolate the effect of the extract against a consistent carbohydrate background.
Results at Day 45
| Measurement | 1,500 mg | 3,000 mg | Placebo |
|---|---|---|---|
| Weight loss | 2.10 kg | 1.94 kg | 0.13 kg |
| BMI reduction | 0.87 kg/m² | 0.76 | 0.24 |
| Waist circumference | −6.4 cm | −6.2 cm | −1.5 cm |
| Hip circumference | −8.2 cm | −6.6 cm | −2.6 cm |
| Thigh circumference | −7.7 cm | −5.9 cm | −0.7 cm |
| Subcutaneous fat thickness | −24.9 mm | −22.4 mm | −0.1 mm |
All between-group differences were statistically significant (p<0.01). The most unexpected finding was that the lower 1,500 mg dose outperformed the 3,000 mg dose on every measured parameter. The research team suggested that excessive enzyme inhibition at higher doses may broadly disrupt nutrient absorption, potentially triggering compensatory responses that reduce overall efficacy.
How It Works
Phaseolean’s active compound inhibits alpha-amylase, a digestive enzyme produced in the salivary glands and pancreas that breaks down complex carbohydrates (rice, bread, pasta, starchy vegetables) into glucose. When alpha-amylase is partially blocked, a portion of ingested starch passes through the small intestine undigested, reducing caloric absorption from that meal.
A secondary pathway under investigation is prebiotic activity: the undigested carbohydrates may serve as substrate for beneficial gut bacteria in the colon. This mechanism was not measured in the current trial, though preclinical research has raised the possibility.
Safety and Biomarkers
No adverse events were reported over the 45-day period. Liver function markers, kidney function markers, fasting glucose, and lipid profiles all remained within normal clinical ranges for both active groups. This aligns with a separate 2024 trial published in Scientific Reports (81 participants, 12 weeks, Phase 2 extract) that also reported good tolerability at 700 and 1,000 mg doses taken three times daily.
Context and Limitations
The benefit is specifically tied to carbohydrate intake. On a low-carbohydrate or protein-dominant eating pattern, there is minimal substrate for the inhibitor to act on. The 61% carbohydrate diet used in this study was deliberately chosen to provide a relevant target.
The study’s limitations are worth noting: single-center design, 45-day duration, and a relatively small completion group of 62 participants. Long-term weight maintenance data and any rebound effect after discontinuation are not available from this trial. The combination of dietary control and exercise also makes it difficult to attribute all observed changes solely to the extract.
If You Take Blood Sugar Medications
Changes in carbohydrate absorption can shift postprandial blood glucose patterns. Anyone using insulin, metformin, or other glucose-lowering medications should consult a healthcare provider before adding a carb-blocking supplement. Safety data in pregnancy and breastfeeding is insufficient.
White kidney bean extract is not a substitute for overall dietary quality. What the evidence suggests is that for people eating a carbohydrate-forward diet, a standardized alpha-amylase inhibitor may serve as a practical adjunct, one that does not require restructuring the entire plate to produce a measurable metabolic effect. Two proprietary ingredients dominate the market currently: Phase 2 and Phaseolean. This trial used the latter.